HoLEP vs. Aquablation: How Do the BPH Procedures Compare?

Both HoLEP and Aquablation relieve urinary symptoms from an enlarged prostate to a similar degree, with nearly identical improvements in symptom scores at the one-year mark. Where the two procedures diverge is in everything around that core outcome: ejaculation preservation, bleeding risk, serious complication rates, and how much prostate tissue actually gets removed. For many men, the “right” choice hinges less on how well each clears the obstruction and more on which tradeoffs matter most to them personally.

How Each Procedure Works

HoLEP, short for holmium laser enucleation of the prostate, uses a laser fiber inserted through the urethra to peel the enlarged inner gland away from the surrounding capsule. The surgeon typically follows a three-lobe approach, starting with incisions around the middle lobe and then working along both lateral lobes until the entire adenoma is freed and pushed into the bladder.¹ A morcellator then chops the tissue into small pieces for removal. Because the laser traces along the natural plane between the adenoma and the capsule, HoLEP removes a large proportion of the obstructing tissue in a single session.

Aquablation takes a fundamentally different approach. A robotic handpiece delivers a high-velocity jet of saline, guided by real-time ultrasound imaging. The surgeon maps the treatment zone on a screen, essentially drawing the area to be ablated, and then the robot executes the cut with the waterjet.² Because the saline stream is heat-free, it tends to destroy soft glandular tissue while sparing tougher collagen-based structures like blood vessels and the ejaculatory ducts.³ After the waterjet finishes, low-energy cautery or a laser is used to control bleeding at the treated surface.

The practical difference boils down to this: HoLEP is a manual, surgeon-driven enucleation that strips out the adenoma as completely as possible. Aquablation is a robotically assisted ablation that carves a channel through the obstructing tissue using a preset surgical plan. One removes nearly the whole adenoma; the other removes enough to open the channel.

Symptom Relief Is Essentially a Tie

The metric urologists lean on most heavily is the International Prostate Symptom Score (IPSS), a questionnaire that captures how much urinary bother a man experiences. In a prospective study comparing the two procedures, average IPSS dropped from roughly 20 at baseline to about 6 at 12 months for both groups, with no meaningful difference between them.⁴ That kind of improvement, from moderate-to-severe symptoms down to mild, is what both procedures are designed to achieve, and neither consistently outperforms the other on this front.

Where things get slightly more interesting is in the early recovery window. The same study found that at three months, Aquablation patients reported better ejaculatory and continence function than HoLEP patients. But by six and twelve months, those early differences had evened out, and the two groups looked the same on erectile function, ejaculatory function, continence, and overall urinary symptom reduction.⁵ So if you are weighing the two purely on “how much better will I pee,” the answer at one year is basically the same.

Ejaculation Preservation Is Where Aquablation Pulls Ahead

For many men, especially those who are younger or sexually active, the ability to preserve ejaculation after prostate surgery is a major concern. This is where Aquablation shows its clearest advantage. A propensity-matched study comparing sexually active patients found that about three-quarters of Aquablation patients retained ejaculation, compared to fewer than half in the HoLEP group.⁶ When looking specifically at men who maintained or improved their ejaculatory function compared to before surgery, the gap widened further: about 68% for Aquablation versus roughly 19% for HoLEP.

A separate prospective study painted an even starker picture, reporting ejaculatory preservation in about 83% of Aquablation patients compared to 18% of HoLEP patients.⁷ Erectile function, on the other hand, was preserved in both groups. The mechanism behind Aquablation’s advantage here is straightforward: because the waterjet selectively destroys soft glandular tissue while leaving tougher collagen-rich structures intact, it tends to spare the ejaculatory ducts and bladder neck in ways that a laser enucleation, which strips away everything down to the capsule, simply cannot.

The exact numbers vary between studies because of differences in sample sizes and how ejaculation was measured. But the direction of the finding is consistent and fairly dramatic. If preserving ejaculation is a high priority, this is the single strongest argument in Aquablation’s favor.

Continence Recovery

Stress urinary incontinence, the involuntary leaking that happens with coughing, sneezing, or physical effort, is one of the complications men worry about most after prostate surgery. The WATER III trial, which compared Aquablation directly against laser enucleation, found that persistent stress urinary incontinence was absent in the Aquablation group versus about 9% in the laser enucleation group.⁸

That said, the smaller prospective study discussed earlier showed a more nuanced picture: Aquablation patients had better continence scores at three months, but by 12 months the difference was no longer significant.⁹ The takeaway is that continence recovery may be faster with Aquablation, and there may be a small long-term advantage for persistent stress incontinence, but the evidence is mixed enough that this should not be the sole deciding factor. The WATER III trial is the larger and more methodologically rigorous of the two, so its finding of a meaningful difference in persistent incontinence carries real weight.

Bleeding Risk and Serious Complications Favor HoLEP

Here is where HoLEP regains ground. A network meta-analysis pooling data from multiple studies found that hemoglobin loss was lower with HoLEP than with Aquablation, and the risk of needing a blood transfusion trended higher with Aquablation, though the difference did not reach statistical significance.¹⁰ This makes mechanical sense: the holmium laser cauterizes tissue as it cuts, providing built-in hemostasis. Aquablation’s waterjet does not generate heat, so bleeding control depends on a separate cautery step performed after the ablation is finished.

In the prospective head-to-head study, serious complications (Clavien-Dindo grade 3 or higher, meaning events that required surgical or radiologic intervention) were significantly more common after Aquablation. Six of 16 Aquablation patients experienced a serious complication, compared to just one of 24 HoLEP patients.¹¹ That is a striking difference, though it comes from a small study. Most of these serious events were related to postoperative bleeding requiring return to the operating room, which aligns with the meta-analysis finding. The early Aquablation literature has consistently flagged perioperative bleeding as its main safety concern, and while techniques for managing it have improved, this remains a meaningful tradeoff.

For a man whose primary concern is avoiding a return trip to the operating room, HoLEP’s hemostatic advantage is worth taking seriously.

How Much Tissue Gets Removed

One of the more underappreciated differences between these two procedures is the sheer volume of tissue each one takes out. HoLEP, because it enucleates the entire adenoma down to the capsule, achieved a prostate volume reduction of about 80% at 12 months in the head-to-head study. Aquablation reduced volume by roughly 39%.¹² Both groups had similar symptom improvement despite this difference, which tells you that you do not necessarily need to remove all the tissue to get good relief. But the long-term implications are an open question. If a large amount of adenoma remains, there is at least a theoretical risk of regrowth and symptom recurrence years down the road. Long-term data beyond five years comparing the two is still limited.

The volume difference also has a practical consequence that often gets overlooked: tissue available for pathology. Because HoLEP removes the entire adenoma and sends it to the lab, it has a much higher chance of catching incidental prostate cancer that was lurking undetected in the gland. A study comparing over 1,200 patients found that incidental prostate cancer was diagnosed in about 6% of HoLEP specimens but in only 0.3% of Aquablation specimens.¹³ This does not mean Aquablation patients had less cancer; it means the procedure simply left most of the tissue in place, so there was far less to examine. For men who have not had prostate cancer ruled out to their satisfaction, HoLEP’s ability to provide a thorough pathology specimen is a meaningful extra benefit.

Operating Time and Practical Logistics

In the prospective comparison, HoLEP was significantly faster, averaging about 60 minutes versus 87 minutes for Aquablation.¹⁴ However, this comparison comes with a caveat. The active tissue-removal phase of Aquablation, when the waterjet is actually firing, is typically quite short, often under 10 minutes. The remaining time is taken up by setup, ultrasound mapping, the separate hemostasis step, and general anesthetic overhead. HoLEP’s operating time, meanwhile, is almost entirely active surgical work, and it varies considerably based on prostate size and surgeon experience.

On the economic side, a pilot study examining Aquablation performed in ambulatory surgery centers (outpatient settings rather than hospitals) found that it generated higher contribution margins than HoLEP, TURP, or GreenLight laser, and saved the healthcare system roughly $1,800 per case compared to hospital-based Aquablation.¹⁵ This is a single pilot study, so the numbers should be taken as preliminary. But it suggests that as Aquablation migrates out of hospitals and into outpatient facilities, its cost profile could become competitive or even favorable. HoLEP, for its part, requires a morcellator and holmium laser system, and in many centers, the capital equipment costs and surgeon training overhead are significant.

The Learning Curve Question

HoLEP is widely acknowledged to have one of the steepest learning curves of any common urologic procedure. The technique demands precise laser control, an intuitive understanding of prostate anatomy in three dimensions, and comfort with morcellation. Most estimates place the learning curve at somewhere around 30 to 50 cases before a surgeon achieves consistent results, and some analyses put it even higher. This has limited HoLEP’s adoption despite decades of evidence supporting its effectiveness; only a fraction of urologists currently perform it.

Aquablation’s proponents argue that its robotic, image-guided design flattens the learning curve substantially. Because the surgeon maps the treatment area on an ultrasound screen and the robot executes the resection, the manual dexterity demands are lower. The counterargument is that managing hemostasis after the waterjet step still requires skill, and the overall workflow, including ultrasound probe positioning and interpreting real-time imaging, is not trivial. Still, the standardized nature of the robotic execution means that case-to-case variability is lower than with HoLEP, which is almost entirely dependent on the individual surgeon’s hands.

Which Prostate Sizes Each Handles Best

HoLEP is considered size-independent. Because the laser enucleates along the capsule regardless of how large the adenoma is, it works on prostates ranging from small to very large, well over 200 grams in experienced hands. In fact, HoLEP’s relative advantage over other procedures grows as the prostate gets bigger, since it can remove massive amounts of tissue in a single session.

Aquablation is currently approved for prostates between 30 and 150 mL in the United States, and most of the clinical trial data comes from glands in the 30 to 150 mL range. The head-to-head trial discussed throughout this article enrolled patients with prostates of at least 50 mL and no more than 150 mL. For very large glands above 150 mL, Aquablation’s incomplete tissue removal becomes a greater concern, and HoLEP or open simple prostatectomy are typically the preferred options. For moderate-sized glands in the 40 to 80 mL range, both procedures are on solid footing, and the choice comes down to the tradeoffs discussed above.

Men with a prominent middle lobe, which juts into the bladder like a ball valve, present an interesting case. Aquablation can target the middle lobe with its waterjet, and the ultrasound mapping is specifically designed to account for it. HoLEP handles middle lobes as part of its standard three-lobe enucleation technique.¹⁶ Neither procedure struggles with this anatomy in experienced hands, but the middle lobe does add complexity to Aquablation’s hemostasis step because of the lobe’s rich blood supply near the bladder neck.

Incidental Cancer Detection as a Hidden Variable

The finding that HoLEP catches incidental prostate cancer at roughly 6% compared to Aquablation’s 0.3% deserves its own consideration, because this is not just a statistical curiosity.¹⁷ Many men undergoing BPH surgery are in the age group where undiagnosed prostate cancer is common. If a man has already had a recent negative biopsy or MRI that makes cancer unlikely, this difference may not matter much. But for a man who has elevated PSA, has declined biopsy, or simply has not been thoroughly evaluated for cancer, HoLEP’s ability to deliver the entire adenoma for pathological examination is a genuine safety net.

Aquablation’s waterjet destroys tissue in situ rather than removing it intact, so the fragments available for analysis are smaller and less representative. This is an inherent limitation of the ablation approach, not a flaw that can be engineered away. If catching occult cancer is a priority, HoLEP has a structural advantage that Aquablation cannot match.

When One Procedure Clearly Beats the Other

Despite the head-to-head studies showing similar symptom relief, the two procedures are not interchangeable for every patient. Some scenarios tip the balance more clearly:

Sexually active men prioritizing ejaculation: Aquablation’s preservation rates are dramatically better across multiple studies. For a man in his 50s or 60s who considers ejaculatory function important, this is a strong reason to favor Aquablation.
Very large prostates above 150 mL: HoLEP is the more proven option. Aquablation’s approval range and evidence base do not extend reliably to very large glands.
Men on blood thinners or with bleeding disorders: HoLEP’s superior hemostasis profile makes it the safer bet. Aquablation’s higher bleeding and transfusion risk is more concerning in patients who already have impaired clotting.
Desire for thorough tissue pathology: HoLEP removes the entire adenoma for examination, giving the pathologist far more material to work with.
Limited access to experienced surgeons: Aquablation’s robotic execution may deliver more consistent results across surgeons with varying experience levels, though this claim still needs more long-term validation.

For the large group of men who fall in the middle, with moderate-sized prostates, no strong feelings about ejaculation, and no unusual bleeding risk, both procedures offer excellent symptom relief. The conversation with a urologist should focus on which complication profile feels more acceptable and what the surgeon’s personal experience and volume are with each technique. A highly experienced HoLEP surgeon is likely to deliver better outcomes with HoLEP than a surgeon performing their fifteenth case of either procedure.